PMID- 23362656
OWN - NLM
STAT- MEDLINE
DCOM- 20130304
LR  - 20191112
IS  - 1181-912X (Print)
IS  - 1181-912X (Linking)
VI  - 22
IP  - 4
DP  - 2012 Autumn
TI  - Counselling and adverse event management for patients with myelodysplastic 
      syndromes undergoing azacitidine therapy: a practice standard for Canadian 
      nurses.
PG  - 222-34
AB  - Azacitidine (5-azacytidine, VIDAZA) is a disease-modifying agent that improves 
      survival, reduces transfusion dependence, and reduces progression to acute 
      myeloid leukemia in patients with higher risk myelodysplastic syndromes. 
      Azacitidine injection is associated with characteristic adverse events (AEs) that 
      must be managed in order for patients to stay on therapy and achieve optimal 
      therapeutic outcomes. These AEs include injection-site reactions, cytopenias, and 
      gastrointestinal effects. Oncology nurses are uniquely positioned to provide 
      patient support and counselling, thereby helping patients and their families set 
      clear expectations for azacitidine therapy. This article presents a nursing 
      standard designed to support Canadian oncology nurses in the key areas of 
      counselling for patients initiating and continuing azacitidine, as well as 
      nursing strategies for prevention and management of azacitidine-associated AEs. 
      Many of the general principles discussed in this nursing standard can be applied 
      broadly to many diseases and treatments.
FAU - Murray, Cindy
AU  - Murray C
AD  - Princess Margaret Hospital, University Health Network, Toronto, ON. 
      Cindy.Murray@uhn.on.ca
FAU - Wereley, Annie
AU  - Wereley A
FAU - Nixon, Shannon
AU  - Nixon S
FAU - Hua-Yung, Carol
AU  - Hua-Yung C
FAU - von Riedemann, Sarah
AU  - von Riedemann S
FAU - Kurtin, Sandra
AU  - Kurtin S
CN  - Canadian Nurses Working Group on Azacitidine in MDS
LA  - eng
LA  - fre
PT  - Journal Article
PL  - Canada
TA  - Can Oncol Nurs J
JT  - Canadian oncology nursing journal = Revue canadienne de nursing oncologique
JID - 9300792
RN  - 0 (Antimetabolites, Antineoplastic)
RN  - M801H13NRU (Azacitidine)
MH  - Antimetabolites, Antineoplastic/adverse effects/*therapeutic use
MH  - Azacitidine/adverse effects/*therapeutic use
MH  - Canada
MH  - *Counseling
MH  - Myelodysplastic Syndromes/drug therapy/*nursing
MH  - *Oncology Nursing
MH  - *Practice Guidelines as Topic
MH  - Workforce
EDAT- 2013/02/01 06:00
MHDA- 2013/03/05 06:00
CRDT- 2013/02/01 06:00
PHST- 2013/02/01 06:00 [entrez]
PHST- 2013/02/01 06:00 [pubmed]
PHST- 2013/03/05 06:00 [medline]
AID - 10.5737/1181912x224222227 [doi]
PST - ppublish
SO  - Can Oncol Nurs J. 2012 Autumn;22(4):222-34. doi: 10.5737/1181912x224222227.